[Effect of neoadjuvant chemotherapy on estrogen and progesterone receptors and P53 and CerbB-2 in breast cancer].
OBJECTIVE
To study the effect to neoadjuvant chemotherapy on estrogen receptor (ER), progesterone receptor (PR), P53 and CerbB-2 expression in patients with breast cancer.


METHODS
From 123 breast cancer patients treated with neoadjuvant chemotherapy, core needle biopsy samples before the chemotherapy and surgical specimens were obtained for assay of ER, PR, P53 and CerbB-2 expression.


RESULTS
ER expression occurred in 46.61% (55/118) of the patients before neoadjuvant chemotherapy and in 66.10% (78/118) of these after surgery showing statistically significant. But the changes in PR, P53 and CerbB-2 expression exhibited no significant difference.


CONCLUSIONS
Significant changes occur in ER expression after neoadjuvant chemotherapy in patients with breast cancer. Neoadjuvant chemotherapy has no significant effects on PR, P53 and CerbB-2 expression in patients with breast cancer.
Bao
Gang
G
Department of breast surgery, Affiliated Hospital, Guiyang Medical University, Guizhou 550001, China.
Yang
De-qi
DQ
Zhou
Bo
B
Liu
Peng
P
Wang
Shu
S
Cheng
Lin
L
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis*; D011960:Receptors, Estrogen / Q000096:biosynthesis*; D011980:Receptors, Progesterone / Q000096:biosynthesis*; D013997:Time Factors; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis*
D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D016159:Tumor Suppressor Protein p53